{"id":30130,"date":"2022-09-07T13:06:47","date_gmt":"2022-09-07T08:06:47","guid":{"rendered":"https:\/\/pr.asianetpakistan.com\/?p=97635"},"modified":"2022-09-07T13:06:47","modified_gmt":"2022-09-07T08:06:47","slug":"philips-announces-new-milestones-in-the-development-of-the-worlds-first-spectral-detector-angio-ct-solution","status":"publish","type":"post","link":"https:\/\/myanmarnewsgazette.com\/philips-announces-new-milestones-in-the-development-of-the-worlds-first-spectral-detector-angio-ct-solution\/","title":{"rendered":"Philips announces new milestones in the development of the world\u2019s first spectral detector angio CT solution"},"content":{"rendered":"
September 7, 2022<\/p>\n
Amsterdam, the Netherlands \u2013<\/strong> Royal Philips<\/u><\/a> (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced new milestones in the development of the world\u2019s first spectral detector angio CT solution – Philips Spectral Angio CT suite<\/u><\/a> – bringing the company\u2019s breakthrough spectral CT imaging technology into an integrated hybrid angio CT suite. By combining its award-winning [1]\u00a0Spectral CT 7500 system<\/u><\/a>\u00a0and its\u00a0Image Guided Therapy System \u2013 Azurion with FlexArm<\/u><\/a>\u00a0\u2013<\/u> in a fully integrated interventional suite solution, Philips aims to give physicians immediate access to these two key imaging modalities in a single room, enabling innovation in minimally-invasive procedures in areas such as oncology, stroke, and trauma care.<\/p>\n Philips today announced a new clinical partner and highlighted clinical studies that focus on the added value of using spectral CT imaging technology during interventional procedures.<\/p>\n Expanding Philips\u2019 clinical network<\/strong> \u201cWe are excited to co-create an innovation that could play a defining role in improving patient care in the space of interventional oncology,\u201d said Mark Burgmans, MD, Head of Interventional Radiology at Leiden University Medical Center. \u201cAdding spectral CT imaging to the interventional suite will enable us to offer new treatment opportunities, avoid moving patients from one imaging suite to another, and offer the unique benefits of spectral CT information when you need it.\u201d<\/p>\n Other leading clinical institutes that Philips is working with on this innovation are Mayo Clinic (Rochester, MN, U.S.) and Baptist Health\u2019s Miami Cardiac & Vascular Institute (Miami, FL, U.S.).<\/p>\n Philips Spectral Angio CT suite combines the company\u2019s latest diagnosis and treatment technologies. Philips Image Guided Therapy System \u2013 Azurion with FlexArm<\/u><\/a>\u00a0\u2013<\/u> is the company\u2019s next-generation image-guided therapy platform, integrating best in class imaging systems, software, and specialized diagnostic and therapeutic devices to support exceptional treatment for the most complex procedures. The addition of Philips\u2019 award-winning Spectral CT 7500 system<\/u><\/a>\u00a0means physicians only need one scan to capture all the spectral information required to differentiate and quantify different tissues. Spectral CT enables improved detection, delineation, and quantification of lesions, leading to better-informed planning for minimally-invasive procedures and more precise interventions. It has already proved its worth in other areas of oncology – for example, it has demonstrated higher sensitivity in detecting malignant findings and improved readings of incidental findings [2][3]. With its ability to improve tissue characterization, the Spectral CT 7500 offers significant benefits over conventional CT.<\/p>\n Through continuous research, Philips is building clinical evidence that supports the added value of spectral CT imaging for diagnosis and treatment guidance.<\/p>\n Research results show better targeted biopsies using spectral CT guidance<\/strong> \u201cWith conventional CT, large masses may appear as a largely uniform mass, making highly targeted biopsy difficult,\u201d said Filippo Piacentino. \u201cBy fusing images from Philips\u2019 XperGuide live needle guidance with images from spectral CT, that are color-coded based on the effective atomic number of tissues and provide a large amount of additional information, we can now investigate the possibility of obtaining better defined biopsy targets with a fewer number of inconclusive biopsies.\u201d<\/p>\n New clinical collaboration on reduction of the risk of tumor recurrence <\/strong> \u201cAnnouncing these important milestones in the development of our unique Philips Spectral Angio CT suite shows our strong commitment and progress in co-creating the future of image-guided therapy,\u201d said Karim Boussebaa, General Manager of Image Guided Therapy Systems at Philips. \u201cBy combining the best of our award-winning modalities into a single suite we aim to unlock new treatment approaches that could benefit both patients and their physicians.\u201d<\/p>\n Visit Philips at CIRSE 2022<\/strong> [1] Minnie Award for Best New Radiology Device<\/u><\/a> For further information, please contact:<\/strong><\/p>\n Joost Maltha Fabienne van der Feer About Royal Philips<\/strong><\/p>\n Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum \u2013 from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com\/newscenter<\/u><\/a>.<\/p>\n Attachment<\/strong><\/p>\n
\nLeiden University Medical Center (Leiden, the Netherlands) has joined Philips\u2019 global network of clinical partners to investigate how its spectral detector angio CT solution could potentially offer new treatment opportunities and improve patient care.<\/p>\n
\nAt this year\u2019s Cardiovascular and Interventional Radiological Society of Europe Annual Meeting (CIRSE 2022<\/u><\/a>, September 10-14, Barcelona, Spain) a presentation is being given by Filippo Piacentino, interventional radiologist at the University of Insubria (Varese, Italy), on the value of spectral CT imaging guidance for performing high-confidence tumor biopsies [4]. The results being presented illustrate the potential for Philips\u2019 spectral CT technology to better guide biopsies by distinguishing between active and non-active regions in a tumor. Ensuring that a biopsy contains a high number of actively dividing cancer cells is important for high-confidence diagnosis.<\/p>\n
\nPhilips also today announced a research collaboration with the University of Pennsylvania (Pennsylvania, PA, U.S.) to study the practicality of using spectral CT-based tissue temperature mapping to provide real-time feedback during tumor thermal ablation procedures to confirm its effectiveness before the patient leaves the room. This will potentially reduce the risk of localized tumor recurrence.<\/p>\n
\nTo learn more about Philips Spectral Angio CT suite, visit Philips at CIRSE 2022<\/u><\/a> and join the Philips symposia in which leading physicians will share their latest clinical insights on using this new imaging approach in interventional oncology. You can register via our dedicated CIRSE 2022 webpage<\/u><\/a>.<\/p>\n
\n[2] Analysis by Aarhus University Hospital Aarhus, Denmark. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
\n[3] Analysis by University Hospital Cleveland, USA. Results from case studies are not predictive of results in other cases. Results in other cases may vary.
\n[4] Filippo Piacentino, \u2018Spectral CT as innovative imaging guidance in large lesions lung biopsies. XperGuide and Z-effective fusion for more defined targets, more diagnostic samplings and more biomarkers information\u2019. CIRSE 2022<\/p>\n
\nPhilips Global Press Office
\nTel: +31\u00a06\u00a010 55 8116
\nEmail:\u00a0joost.maltha@philips.
\nPhilips Image Guided Therapy
\nTel.: +31 622 698 001
\nE-mail: fabienne.van.der.feer@philips.